

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

Claims 1-10 canceled.

11. (currently amended) ~~A~~ An isolated peptide selected from

(a) a peptide comprising the amino acid sequence represented by SEQ ID NO:1;

(b)(a) a peptide comprising of the amino acid sequence represented by SEQ ID

NO:2;

(e)(b) a peptide comprising of the amino acid sequence represented by SEQ ID NO:3; and

(d)(c) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:1, and of the amino acid sequence: X<sub>n</sub>-Met-Ala-Pro-Y<sub>m</sub> in which n is 0 or 1; m is 0 or 1; X is an amino acid residue; and Y is an amino acid residue, wherein said amino acid sequence having has activity of inhibiting angiotensin-converting enzyme and when n is 0, m is not 0;

(e) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:2, and having activity of inhibiting angiotensin-converting enzyme; and

(f) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:3, and having activity of inhibiting angiotensin-converting enzyme.

12. (previously presented) An inhibitor for an angiotensin-converting enzyme, which comprises the peptide according to claim 11 as an active ingredient.

13. (previously presented) A food or drink comprising the peptide according to claim 11.

14. (previously presented) A pharmaceutical composition comprising the peptide according to claim 11 as an active ingredient.

15. (currently amended) The food or drink according to claim 13, which is an agent for preventing and/or treating diseases caused by abnormality of an angiotensin-converting enzyme.

16. (currently amended) The pharmaceutical composition according to claim 14, which is an agent for preventing and/or treating diseases caused by abnormality of an angiotensin-converting enzyme.

17. (previously presented) A method of inhibiting an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide according to claim 11.

18. (currently amended) A method of preventing and/or treating diseases caused by abnormality of an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide according to claim 11.

19. (new): The isolated peptide of claim 11, wherein n is 1 and m is 0.

20. (new): The isolated peptide of claim 11, wherein n is 0 and m is 1.

21. (new): The isolated peptide of claim 19, wherein X is Leu or Arg.

22. (new): The isolated peptide of claim 20, wherein Y is Pro.

23. (new): The isolated peptide of claim 21, wherein n is 1, m is 1, X is Leu or Arg, and Y is Pro.

24. (new): A method of inhibiting an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide of SEQ ID NO:1.

25. (new): A method of treating diseases caused by abnormality of an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide of SEQ ID NO: 1.